TD-198946
CAS No. 364762-86-7
TD-198946( TD-198946 | TD 198946 | TD198946 )
Catalog No. M17496 CAS No. 364762-86-7
TD-198946, a potent chondrogenic agent, is a thienoindazole derivative.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 143 | In Stock |
|
5MG | 222 | In Stock |
|
10MG | 357 | In Stock |
|
25MG | 597 | In Stock |
|
50MG | 851 | In Stock |
|
100MG | 1152 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTD-198946
-
NoteResearch use only, not for human use.
-
Brief DescriptionTD-198946, a potent chondrogenic agent, is a thienoindazole derivative.
-
DescriptionTD-198946 is a thienoindazole derivative, has been found to be active in the studies as a chondrogenic factor. Cell-sheet technology combined with a thienoindazole derivative small compound TD-198946 for cartilage regeneration. A novel disease-modifying osteoarthritis drug candidate targeting Runx1.
-
In VitroTD-198946 is a potent chondrogenic agent. TD-198946 strongly induces chondrogenic differentiation without promoting hypertrophy in cell and metatarsal organ cultures. TD-198946 induces stronger Col2a1 promoter activity than insulin in ATDC5 cells. In C3H10T1/2 cells, ATDC5 cells and primary mouse chondrocytes, TD-198946 dose-dependently stimulates endogenous expression of the chondrocyte markers Col2a1 and Acan, with maximum effects around 1-10 μM.
-
In VivoWhen administered directly into the joint space, TD-198946 successfully prevents and repaires degeneration of the articular cartilage. TD-198946 exerts its effect through the regulation of Runx1 expression, which is downregulated in both mouse and human OA cartilage compared with normal tissue. TD-198946 has disease-modifying effects on progressed osteoarthritis. TD-198946 may prevent the progression of osteoarthritis by acting on the remaining chondrocytes rather than repairing damaged cartilage, it may be most effective as a therapeutic during the early or middle stages of osteoarthritis, before the articular cartilage is fully eroded. Cartilaginous cell-sheets are generated by culturing mouse and canine costal chondrocytes and human mesenchymal stem cells with TD-198946 on temperature-responsive dishes. The transplanted cell-sheets are then successfully used to promote the reconstruction of permanent cartilage, with no evidence of chondrocyte hypertrophy in the knee articular cartilage defects created in mice and canines.
-
SynonymsTD-198946 | TD 198946 | TD198946
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number364762-86-7
-
Formula Weight482.55
-
Molecular FormulaC27H22N4O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 28 mg/mL; 58.03 mM
-
SMILESCn1c2c(CCc3c(sc(c23)Oc2ccc(cc2)OCc2nc3ccccc3cc2)C(=O)N)cn1
-
Chemical Name1-Methyl-8-[4-(quinolin-2-ylmethoxy)phenoxy]-4,5-dihydrothieno[3,4-g]indazole-6-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yano F, et al. A novel disease-modifying osteoarthritis drug candidate targeting Runx1. Ann Rheum Dis. 2013 May;72(5):748-53.
molnova catalog
related products
-
Glycyl-glycine
Glycylglycine (Gly-Gly) is a dipeptide used in biochemical research. It is the simplest of all dipeptides and is used as a starting template for preparation of more complex peptides. Glycine is involved in the body's production of DNA phospholipids and collagen and in the release of energy.
-
Succimer
Succimer is a Lead Chelator. The mechanism of action of succimer is as a Lead Chelating Activity.
-
Vazegepant HCl
Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.